Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngene InternationalNSE:SYNGENE -0.46%79 Days Payable is 136.03 as of Mar. 2026, which is 6% above its 10-year median of 128.30. GuruFocus rates NSE:SYNGENE with a GF Score™ of 79/100 and a GF Value™ of ₹770.19 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Syngene International ranks better than 71.05% on this metric.
The historical rank and industry rank for Syngene International's Days Payable or its related term are showing as below:
NSE:SYNGENE'
s Days Payable Range Over the Past 10 Years
Min: 100.32 Med: 128.3 Max: 160.7
Current: 131.24
During the past 13 years, Syngene International's highest Days Payable was 160.70. The lowest was 100.32. And the median was 128.30.
NSE:SYNGENE's Days Payable is ranked better than 71.05% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs NSE:SYNGENE: 131.24
Syngene International Days Payable Historical Data
* Premium members only.
The historical data trend for Syngene International's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SYNGENE vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Syngene International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's Days Payable distribution charts can be found below:
* The bar in red indicates where Syngene International's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Syngene International's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syngene International (NSE:SYNGENE) has a Days Payable of 136.03 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Syngene International and its competitors. This is near median its historical median of 128.30. Over the past decade, Syngene International's Days Payable has ranged from 100.32 to 160.70. According to the industry distribution chart, Syngene International ranks #55 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 28.9%.
Is Syngene International's Days Payable too high?
Syngene International's current Days Payable of 136.03 is near median its 10-year median of 128.30. Over the past 10 years, this metric has ranged from a low of 100.32 to a high of 160.70. The Medical Diagnostics & Research industry median Days Payable is 64.64. Syngene International's value of 136.03 is 110.4% above this industry median. Based on the distribution chart, Syngene International ranks #55 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Syngene International has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Syngene International ranks #55 out of 190 companies for Days Payable. This puts Syngene International in the upper half of its industry. The industry median Days Payable is 64.64. Syngene International's value of 136.03 is 110.4% above this benchmark. Historically, Syngene International's own Days Payable has ranged from 100.32 to 160.70 over the past decade. While the company's 10-year median is 128.30 vs. the industry median of 64.64, Syngene International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syngene International's current Days Payable of 136.03 is 110.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Syngene International and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngene International's current Days Payable is 136.03, which is near median its own 10-year median of 128.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (NSE:SYNGENE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹770.19, compared to a current price of ₹417.45 — trading 45.8% below its estimated fair value. The current Days Payable is 136.03, which is near median its 10-year median of 128.30 and 110.4% above the Medical Diagnostics & Research industry median of 64.64. Syngene International's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Syngene International (NSE:SYNGENE), the current Days Payable is 136.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (NSE:SYNGENE) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹417.45 is trading 45.8% below its estimated GF Value™ of ₹770.19.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for NSE:SYNGENE:
Days Payable: 136.03 (near median its 10-year median of 128.30)
GF Value™: ₹770.19 vs. price of ₹417.45 (45.8% below fair value)
Industry Position: 110.4% above the Medical Diagnostics & Research median (#55 of 190)
No single metric tells the full story. See the NSE:SYNGENE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
79GF Score
Get the complete analysis for NSE:SYNGENE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SYNGENE has been successfully added to your 
